Cereno Scientific’s innovative drug candidate CS585 featured as one of the future antiplatelet strategies in the top-tier Journal of Thrombosis and Haemostasis
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that a review article titled “Antiplatelet strategies: past, present, and future” highlighted the company's innovative drug candidate CS585 as a promising future strategy in reducing platelet activity. The review article published in the prestigious Journal of Thrombosis and Haemostasis 20th anniversary issue in December further states that antiplatelet therapy plays a critical role in the prevention and treatment of major cardiovascular diseases triggered by thrombosis.
“We are incredibly proud and encouraged by the recognition of our innovative drug candidate CS585 in the prestigious Journal of Thrombosis and Haemostasis (JTH). This highlights not only the potential of CS585 as a future strategy in antiplatelet therapy but also Cereno Scientific's commitment to advancing the treatment of cardiovascular diseases. The recent findings presented at the ASH Annual Meeting, coupled with the positive preclinical results published in Blood and now the recognition in the current review on existing and future antiplatelet therapy in JTH, reinforces our belief that CS585 could mark a significant milestone in the field. Our focus remains on developing treatments that offer enhanced efficacy and safety, and this acknowledgment is a testament to the hard work and dedication of our team in achieving these goals,” said Sten R. Sörensen, CEO, Cereno Scientific.
Drug candidate CS585 is currently in preclinical phase and is being evaluated as a treatment for cardiovascular disease. CS585 was inlicensed from University of Michigan in 2023 with full exclusive development and commercialization rights. There is a growing body of evidence around drug candidate CS585 supporting favorable tolerability and efficacy in preclinical studies. At the ASH Annual Meeting in December, new preclinical data presented CS585 compared to two FDA-approved drugs (iloprost and selexipag) that showed CS585 to be more selective and to have sustained efficacy, i.e. substantially longer than the currently available IP receptor agonists. Recently, initial preclinical results were published in the top-tier journal Blood showing that the drug candidate CS585 is a highly potent and selective antiplatelet, given both orally and intravenously and prevents thrombosis for up to 48 hours after dose without increasing the risk of bleeding. Following the publication in Blood, a commentary article and the Blood Podcast highlighted that CS585 could mark a significant milestone to improve anti-thrombotic treatment strategies without causing bleeding.
Access the review article: Stanger L., Yamaguchi A., and Holinstat M. Antiplatelet strategies: past, present, and future. JTH 20th anniversary review article, volume 21, issue 12, p3317-3328, December 2023. DOI: https://doi.org/10.1016/j.jtha.2023.09.013
For further information, please contact:
Tove Bergenholt, Director IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 732-366 246
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q2 2024. After requests by investigators in the Phase II study, a “compassionate use” application for CS1 is currently being pursued. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.